International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com,
announced today that its Chairman, Kenneth Aldrich and the CEO of its
Lifeline Skin Care subsidiary, Ruslan Semechkin, PhD, will present a
Webinar discussion of the State of the Company and its plans for its
Skin Care subsidiary on Wednesday, January 19, 2011 at 10:00 a.m. PST.
In announcing the event, Mr. Aldrich stressed that its purpose is not to
announce any new programs or financial results, but to attempt to
provide an overview of events during the past year and offer
shareholders a perspective on what to expect in the coming year. The
dial-in number for participants is: 1 (800) 588-4973. Please provide the
confirmation number 28808144 to the operator upon calling in. An
alternate dial-in number is 1 (847) 230-5643. The confirmation number
will be the same for both numbers. A replay of the call will be
available on the home page of the company's website at: http://www.internationalstemcell.com.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology
company focused on the therapeutic applications of human parthenogenetic
stem cells and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology, parthenogenesis,
results in creation of pluripotent human stem cells from unfertilized
oocytes (eggs). hpSCs avoid ethical issues associated with the use or
destruction of viable human embryos. ISCO scientists have created the
first parthenogenic, homozygous stem cell line that can be a source of
therapeutic cells with minimal immune rejection after transplantation
into hundreds of millions of individuals of differing sexes, ages and
racial groups. This offers the potential to create the first true stem
cell bank, UniStemCell™, while avoiding the ethical issue of using
fertilized eggs. ISCO also produces and markets specialized cells and
growth media for therapeutic research worldwide through its subsidiary
Lifeline Cell Technology and cell-based skin care products through its
subsidiary Lifeline Skin Care. More information is available at ISCO's
website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Ruslan
Semechkin, PhD,
Vice President, ISCO, CEO Lifeline Skin Care
ras@intlstemcell.com |
